Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial

INTRODUCTION: Tyrosine kinase inhibitors (TKI) are medications of interest in the treatment of Systemic Sclerosis (SSc) because of their ability to inhibit pathways involved in fibrosis. In this open-label pilot trial, our objectives were to assess the safety, efficacy, and molecular change associat...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Arthritis Res Ther
Asıl Yazarlar: Gordon, Jessica K., Martyanov, Viktor, Magro, Cynthia, Wildman, Horatio F., Wood, Tammara A., Huang, Wei-Ti, Crow, Mary K., Whitfield, Michael L., Spiera, Robert F.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2015
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4538758/
https://ncbi.nlm.nih.gov/pubmed/26283632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-015-0721-3
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller